Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hongqiu Pan

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Clinical Pharmacy and Therapeutics|April 26, 2022
The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injuryMeiling Zhang, Jia Zhu, Nannan Wang, et al.
Pharmacogenomics|April 26, 2022
Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in ChinaWenpei Liu, Lihuan Lu, Hongqiu Pan, et al.
Fundamental & Clinical Pharmacology|June 29, 2025
Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug-Induced Liver Injury in ChinaJingru Cheng, Nannan Wang, Ruina Chen, et al.
Frontiers in Medicine|August 31, 2023
A prospective multicenter clinical research study validating the effectiveness and safety of a chest X-ray-based pulmonary tuberculosis screening software JF CXR-1 built on a convolutional neural network algorithmYang Yang, Lu Xia, Ping Liu, et al.
Plos One|May 21, 2015
Is tuberculosis treatment really free in China? A study comparing two areas with different management modelsSangsang Qiu, Hongqiu Pan, Simin Zhang, et al.
Pakistan Journal of Pharmaceutical Sciences|June 25, 2025
Baseline keratin-18 level and risk of anti-tuberculosis drug-induced liver injury: An individual matched case-control studyBing Han, Min Zhu, Yiwen He, et al.
BMJ Open|April 1, 2019
Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational studyMiaomiao Yang, Hongqiu Pan, Lihuan Lu, et al.
American Journal of Respiratory and Critical Care Medicine|March 11, 2021
Glycemic Trajectories and Treatment Outcomes of Patients with Newly Diagnosed Tuberculosis: A Prospective Study in Eastern ChinaQiao Liu, Nannan You, Hongqiu Pan, et al.
Therapie|June 16, 2022
The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis : A case-control studyWenpei Liu, Nannan Wang, Jia Zhu, et al.
Fundamental & Clinical Pharmacology|March 1, 2023
Relationship between common telomere length-related genetic variations, telomere length, and risk of antituberculosis drug-induced hepatotoxicity in Chinese Han population: As assessed for causality using the updated Roussel Uclaf Causality Assessment MethodXinyu Chen, Zhuolu Hao, Hongqiu Pan, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Clinical Pharmacy and Therapeutics|April 26, 2022
The role of the genetic variant FECH rs11660001 in the occurrence of anti-tuberculosis drug-induced liver injuryMeiling Zhang, Jia Zhu, Nannan Wang, et al.
Pharmacogenomics|April 26, 2022
Heme oxygenase-1 and hemopexin gene polymorphisms and the risk of anti-tuberculosis drug-induced hepatotoxicity in ChinaWenpei Liu, Lihuan Lu, Hongqiu Pan, et al.
Fundamental & Clinical Pharmacology|June 29, 2025
Effects of FECH Gene Polymorphisms and Serum Ferrochelatase Levels on Antituberculosis Drug-Induced Liver Injury in ChinaJingru Cheng, Nannan Wang, Ruina Chen, et al.
Frontiers in Medicine|August 31, 2023
A prospective multicenter clinical research study validating the effectiveness and safety of a chest X-ray-based pulmonary tuberculosis screening software JF CXR-1 built on a convolutional neural network algorithmYang Yang, Lu Xia, Ping Liu, et al.
Plos One|May 21, 2015
Is tuberculosis treatment really free in China? A study comparing two areas with different management modelsSangsang Qiu, Hongqiu Pan, Simin Zhang, et al.
Pakistan Journal of Pharmaceutical Sciences|June 25, 2025
Baseline keratin-18 level and risk of anti-tuberculosis drug-induced liver injury: An individual matched case-control studyBing Han, Min Zhu, Yiwen He, et al.
BMJ Open|April 1, 2019
Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational studyMiaomiao Yang, Hongqiu Pan, Lihuan Lu, et al.
American Journal of Respiratory and Critical Care Medicine|March 11, 2021
Glycemic Trajectories and Treatment Outcomes of Patients with Newly Diagnosed Tuberculosis: A Prospective Study in Eastern ChinaQiao Liu, Nannan You, Hongqiu Pan, et al.
Therapie|June 16, 2022
The relationship between relative telomere length and anti-tuberculosis drug-induced hepatitis : A case-control studyWenpei Liu, Nannan Wang, Jia Zhu, et al.
Fundamental & Clinical Pharmacology|March 1, 2023
Relationship between common telomere length-related genetic variations, telomere length, and risk of antituberculosis drug-induced hepatotoxicity in Chinese Han population: As assessed for causality using the updated Roussel Uclaf Causality Assessment MethodXinyu Chen, Zhuolu Hao, Hongqiu Pan, et al.
Pageof 5